ReviewLife (Basel, Switzerland)2023
Pityriasis Versicolor-A Narrative Review on the Diagnosis and Management.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07331792 (Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Trial
- Erythematous pityriasis versicolor: a case report and review of the literature.Skin health and disease · 2026Article
- Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance.International journal of molecular sciences · 2026Review
- Early-Onset Neonatal Pityriasis Versicolor Associated With Maternal Infection: A Case Report From Uganda.Clinical case reports · 2026Article
- Chromatic Variants of Pityriasis Versicolor and Molecular Species Identification Using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP).Journal of fungi (Basel, Switzerland) · 2026Article
- Cutaneous Fungal Infections in Greek Competitive Swimmers: A Cross-Sectional, Self-Reported Study.Journal of fungi (Basel, Switzerland) · 2026Article
- Atrophying Pityriasis Versicolor: A Rare Presentation of a Common Dermatological Disorder and Literature Review.Case reports in dermatological medicine · 2026Article
- Article
- Sulfur and Its Derivatives in Dermatology: Insights Into Therapeutic Applications-A Narrative Review.Journal of cosmetic dermatology · 2025Review
- The Human Mycobiome: Composition, Immune Interactions, and Impact on Disease.International journal of molecular sciences · 2025Review
- When Pityriasis Versicolor wears a vitiligo mask: a puzzle in an immunocompromised patient.Oxford medical case reports · 2025Article
- Application of Wood's Lamp in Dermatological and Dental Photodiagnostics.Sensors (Basel, Switzerland) · 2025Article
- Ultraviolet-induced Fluorescence Dermatoscopy Unmasks Dermatoscopically Inconspicuous Terra Firma-Forme Dermatosis and Pityriasis Versicolor.Dermatology practical & conceptual · 2025Article
- Terra Firma-Forme Dermatosis: Clinical Insights, Dermoscopic and Ultraviolet-Induced Fluorescence Dermoscopy Findings-A Case Report and Literature Review.Case reports in pediatrics · 2025Article
- Intelligent Diagnosis of Hypopigmented Dermatoses and Intelligent Evaluation of Vitiligo Severity on the Basis of Deep Learning.Dermatology and therapy · 2024Article
- Applications of Ultraviolet and Sub-ultraviolet Dermatoscopy in Neoplastic and Non-neoplastic Dermatoses: A Systematic Review.Dermatology and therapy · 2024Review
- Ultraviolet-Induced Fluorescence Dermoscopy, a Novel Diagnostic Technique in Dermatological Practice: A Systematic Review.Indian dermatology online journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This narrative review presents a comprehensive overview of the diagnosis and management of pityriasis versicolor (PV), a common superficial fungal infection caused by the yeast Malassezia. PV is characterised by scaly hypopigmented or hyperpigmented patches, primarily affecting the upper trunk, neck, and upper arms. Regarding commensal interactions, Malassezia utilises nutrient sources without affecting the human host. In cases of pathogenicity, Malassezia can directly harm the host via virulence factors or toxins, or indirectly by triggering damaging host responses. The diagnosis typically relies on recognising characteristic clinical features. Due to the wide variability in its clinical presentation, recognising the differential diagnosis is critical. In this paper, we discuss the clinical differentials, with their dermatoscopic presentation, but also describe a range of helpful diagnostic techniques (microscopy, conventional and ultraviolet-induced fluorescence dermatoscopy, and confocal microscopy). Topical therapies are the primary treatment for PV, encompassing non-specific antifungal agents like sulphur with salicylic acid, selenium sulphide 2.5%, and zinc pyrithione. Additionally, specific topical antifungal medications with either fungicidal or fungistatic properties may also be incorporated into the topical treatment regimen, such as imidazoles, allylamines, and ciclopirox olamine. Systemic therapies might occasionally be used. Patient education and the promotion of good personal hygiene are pivotal to reduce the risk of recurrence. In recurrent cases, particularly during warmer and more humid periods, prolonged prophylaxis with topical agents should be considered.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.